![Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study | BMJ Open Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/6/2/e010313/F2.large.jpg)
Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study | BMJ Open
![Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial - The Lancet Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2b0c5fe8-d7eb-4483-b185-176f340ad2b7/gr1.gif)
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial - The Lancet
PLOS ONE: Why do open-label placebos work? A randomized controlled trial of an open-label placebo induction with and without extended information about the placebo effect in allergic rhinitis
PLOS ONE: Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial
![Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f088fbaa-3134-4ce6-8294-01c8c23f249b/gr1.gif)
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial - The Lancet
![Effects of open-label placebos on test performance and psychological well-being in healthy medical students: a randomized controlled trial | Scientific Reports Effects of open-label placebos on test performance and psychological well-being in healthy medical students: a randomized controlled trial | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-81502-2/MediaObjects/41598_2021_81502_Fig1_HTML.png)
Effects of open-label placebos on test performance and psychological well-being in healthy medical students: a randomized controlled trial | Scientific Reports
![Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open- label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open- label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2883e24f-ded5-4447-96b4-db02193741ca/gr1.gif)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open- label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology
![Hydroxychloroquine for COVID-19: What do the clinical trials tell us? - The Centre for Evidence-Based Medicine Hydroxychloroquine for COVID-19: What do the clinical trials tell us? - The Centre for Evidence-Based Medicine](https://www.cebm.net/wp-content/uploads/2020/04/Jeff_Robin.jpg)
Hydroxychloroquine for COVID-19: What do the clinical trials tell us? - The Centre for Evidence-Based Medicine
![Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial) Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)](https://bmjopen.bmj.com/content/bmjopen/5/12/e009562/F1.large.jpg)
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)
![An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19 - eClinicalMedicine An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19 - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2f77f968-1e6c-49f4-9f56-a42b48f4fb05/gr1.jpg)
An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19 - eClinicalMedicine
![Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial - The Lancet Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f21db88d-be5a-4c5c-8750-1a2940593250/gr1.gif)
Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial - The Lancet
![Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled trial - The Lancet Gastroenterology & Hepatology Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled trial - The Lancet Gastroenterology & Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2110455949/2083206708/gr1.gif)
Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled trial - The Lancet Gastroenterology & Hepatology
![How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download](https://images.slideplayer.com/23/6590870/slides/slide_3.jpg)
How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download
![Adaptive designs in clinical trials: why use them, and how to run and report them | BMC Medicine | Full Text Adaptive designs in clinical trials: why use them, and how to run and report them | BMC Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12916-018-1017-7/MediaObjects/12916_2018_1017_Fig1_HTML.gif)
Adaptive designs in clinical trials: why use them, and how to run and report them | BMC Medicine | Full Text
![Expired Breath Carbon Monoxide Levels in a 14Week Open-Label Trial of... | Download Scientific Diagram Expired Breath Carbon Monoxide Levels in a 14Week Open-Label Trial of... | Download Scientific Diagram](https://www.researchgate.net/profile/James-Gold-2/publication/12050357/figure/fig1/AS:601716932231173@1520471904467/Expired-Breath-Carbon-Monoxide-Levels-in-a-14Week-Open-Label-Trial-of-Supportive-Group.png)